gp130 (OSMR)

Class

Cytokine receptor antagonist monoclonal antibody

Gp130 is a receptor subunit shared by an entire family of signaling proteins called interleukin-6 (IL-6) family cytokines. It does not bind these signaling molecules alone; instead it pairs with a second, cytokine-specific receptor chain to form a functional receptor complex. One such partner is OSMR, which combines with gp130 to receive signals from oncostatin M, and which also pairs with a separate receptor chain to receive signals from interleukin-31, a cytokine strongly linked to itch. Because OSMR sits at the intersection of both pathways, antibodies that block OSMR can dampen signaling from two distinct inflammatory cytokines at once. This is biologically relevant in chronic inflammatory and itch-associated skin conditions, where oncostatin M and IL-31 both contribute to tissue inflammation, barrier disruption, and the sensation of itch. Modulating this receptor offers a way to interrupt a shared signaling node rather than pursuing two separate drugs against two separate cytokines. More broadly, cytokine receptor antagonism of this kind reflects a general pharmacological strategy: targeting a convergence point in a signaling network to achieve broader pathway control with a single agent, applicable across inflammatory, fibrotic, and pruritic disease contexts.